Newly appointed CEO has over 20 years’ experience in company building and strategic business development London UK / Cambridge, MA USA, 25 July 2023 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive […]
Dr. Ottesen brings in-depth global clinical development expertise in oncology, including biologics, small molecules, immunotherapies and ADCs Adcendo further builds its world class team to accelerate development of lead ADC asset uPARAP and to expand its first-in-class ADC pipeline Copenhagen, Denmark, June 20, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of […]
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology Lonza and Synaffix will continue to expand their Center of Excellence for bioconjugate technology development, […]
Strengthening of strategic option license agreement to cover additional novel ADC targets Copenhagen, Denmark, May 30th, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, announced the expansion of its current collaboration with Duality Biologics (“Duality”), a clinical-stage […]
Data demonstrate that uPARAP is widely expressed at high levels across multiple sarcoma subtypes Strong overexpression in tumors combined with low expression levels in normal human tissues makes uPARAP an attractive candidate for therapeutic targeting of sarcomas by antibody-drug conjugates (ADCs) Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the […]
